Long-Term (52-Week) Results Of a Phase 3, Randomized, Controlled Trial Of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients With Psoriatic Arthritis and Current Skin Involvement (PALACE 3)
Services
Services
Date issued
2013Journal title
ARTHRITIS AND RHEUMATISM
Type of content
Publicación de congreso
